NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球藥事申請 (RA) 服務的市場趨勢·市場佔有率·市場規模的預測 (2020-2027年): 服務·服務供應商·企業規模·類別·開發階段·適應症·終端用戶·各地區

Regulatory Affairs Market Size, Share & Trends Analysis Report By Service, By Service Provider, By Company Size, By Categories, By Product Stage, By Indication, By End-use, By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 977797
出版日期 內容資訊 英文 187 Pages
商品交期: 2-3個工作天內
價格
全球藥事申請 (RA) 服務的市場趨勢·市場佔有率·市場規模的預測 (2020-2027年): 服務·服務供應商·企業規模·類別·開發階段·適應症·終端用戶·各地區 Regulatory Affairs Market Size, Share & Trends Analysis Report By Service, By Service Provider, By Company Size, By Categories, By Product Stage, By Indication, By End-use, By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年11月13日內容資訊: 英文 187 Pages
簡介

全球藥事申請 (RA) 服務的市場規模在預測期間內預計將以8.4%的年複合成長率推移,並成長到2027年209億美元的規模。藥品批准增加,批准產品的標籤擴大以及快速進入市場等因素正在推動市場的增長。此外,法律和法規軟體的技術進步以及醫療行業的數位化轉型有望為市場增長做出貢獻。

本報告提供全球藥事申請 (RA) 服務的市場調查,彙整市場及服務概要,市場成長的各種影響因素分析,市場規模的轉變·預測,服務·服務供應商·企業規模·類別·開發階段·適應症·終端用戶·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 調查手法·調查範圍

第2章 摘要整理

第3章 市場可變因素·趨勢·展望

  • 市場分類·範圍
  • 市場動態
  • 普及·成長預測製圖
  • 產業課題
  • 主要的交易·策略性聯盟分析
  • 市場分析工具

第4章 市場預測·趨勢分析:各類服務

  • 市場佔有率實際成果·預測
  • 諮詢
  • 法定代理人
  • 文件作成·公開
  • 產品登記·臨床試驗申請
  • 其他

第5章 市場預測·趨勢分析:各服務供應商

  • 市場佔有率實際成果·預測
  • 公司內部
  • 外包

第6章 市場預測·趨勢分析:不同企業規模

  • 市場佔有率實際成果·預測
  • 小規模經營者
  • 中規模經營者
  • 大企業

第7章 市場預測·趨勢分析:各類別

  • 市場佔有率實際成果·預測
  • 藥物
  • 生技藥品
  • 醫療設備

第8章 市場預測·趨勢分析:各開發階段

  • 市場佔有率實際成果·預測
  • 前臨床階段
  • 臨床階段
  • PMA

第9章 市場預測·趨勢分析:各適應症

  • 市場佔有率實際成果·預測
  • 腫瘤
  • 神經
  • 心臟病
  • 免疫
  • 其他

第10章 市場預測·趨勢分析:各終端用戶

  • 市場佔有率實際成果·預測
  • 醫療設備企業
  • 製藥企業
  • 生物科技企業

第11章 市場預測·趨勢分析:各地區·主要國家

  • 市場佔有率實際成果·預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第12章 企業簡介

  • Accell Clinical Research, LLC.
  • GenPact Ltd.
  • Criterium, Inc.
  • PRA Health Sciences
  • Promedica International
  • WuXi AppTec, Inc.
  • Medpace
  • Charles River Laboratories International, Inc.
  • Icon plc
  • Covance
  • Parexel International Corporation
  • Freyr
目錄
Product Code: GVR-4-68039-065-9

Regulatory Affairs Market Growth & Trends:

The global regulatory affairs market size is expected to reach USD 20.9 billion by 2027 registering a CAGR of 8.4%, according to a new report by Grand View Research, Inc. Rise in drug approvals, label expansions of approved products, along with the presence of Fastrack regulatory pathways are anticipated to facilitate the market growth over the forecast period. Technological advancements in regulatory software and the growing digital transformation in the healthcare industry are also expected to contribute to market growth. In addition, the introduction of Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR) is anticipated to not only change the EU regulatory landscape and increase the stringency of regulations but also increase the number of documents required to be created and maintained by companies.

Furthermore, the changes in the Central Administration for Pharmaceutical Affairs (CAPA) scope in Egypt is anticipated to change the medical device registration process in the country. Such changes in local regulations are anticipated to favor market growth. Furthermore, several regulatory changes related to clinical trials, vaccine development, and product approvals, initiated by the global and local regulatory authorities to expedite patient access to Covid-19 treatments and vaccines, are anticipated to positively affect the market growth. Market players are actively involved in the adoption of advanced technologies, strategic collaborations, and mergers & acquisition, to strengthen their market positions and outperform the competition. For instance, in 2020, ICON acquired MedPass, a medical device CRO, reimbursement, and regulatory consultancy firm. This acquisition is aimed at strengthening the medical device and diagnostic research services portfolio of ICON through the addition of new clinical and regulatory capabilities in Europe.

Regulatory Affairs Market Report Highlights:

  • Regulatory writing and publishing was the leading service segment in 2019 and is projected to retain its dominant position throughout the forecast years
  • This growth is credited to an increase in the outsourcing of selected regulatory functions by major life sciences companies
  • The Biologics segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing popularity of personalized medicines and biosimilars
  • The oncology indication segment dominated the market in 2019 and will expand further at a steady CAGR from 2020 to 2027
  • This growth can be attributed to the rising cancer cases and mortality rate along with the presence of several innovative pipeline products

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Region Wise Market Calculation
    • 1.6.1 Region-wise market: Base estimates
    • 1.6.2 Global market: CAGR calculation
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective - 1
    • 1.8.2 Objective - 2
    • 1.8.3 Objective - 3
    • 1.8.4 Objective - 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Regulatory Affairs Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation and Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Changing regulatory landscape
      • 3.2.1.2 Entry of companies in the global market
      • 3.2.1.3 Life science companies focusing on their core competencies
      • 3.2.1.4 Economic and competitive pressures
      • 3.2.1.5 Demand for the faster approval process for breakthrough drugs and devices
      • 3.2.1.6 Growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Risk associated with data security
      • 3.2.2.2 Monitoring issues and lack of standardization
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Industry Challenges
    • 3.4.1 Managing relationships
  • 3.5 Major Deals and Strategic Alliances Analysis
  • 3.6 Major Deals and Strategic Alliances Analysis (Biotech & ATMPs)
  • 3.7 Regulatory affairs: Market Analysis Tools
    • 3.7.1 SWOT
    • 3.7.2 Industry analysis - Porter's
    • 3.7.3 PESTEL analysis

Chapter 4 Regulatory affairs Market: Service Segment Analysis

  • 4.1 Regulatory affairs: Service Market Share Analysis, 2019 & 2027
  • 4.2 Regulatory Consulting
    • 4.2.1 Regulatory consulting market, 2016 - 2027 (USD Million)
  • 4.3 Legal Representation
    • 4.3.1 Legal representation market, 2016 - 2027 (USD Million)
  • 4.4 Regulatory Writing and Publishing
    • 4.4.1 Regulatory writing and publishing market, 2016 - 2027 (USD Million)
  • 4.5 Product Registration and Clinical Trial Application
    • 4.5.1 Product registration and clinical trial application market, 2016 - 2027 (USD Million)
  • 4.6 Other Regulatory Services
    • 4.6.1 Other regulatory services market, 2016 - 2027 (USD Million)

Chapter 5 Regulatory Affairs Market: Service Provider Segment Analysis

  • 5.1 Regulatory Affairs: Service Provider Market Share Analysis, 2019 & 2027
  • 5.2 In-house
    • 5.2.1 In-house regulatory affairs market, 2016 - 2027 (USD Million)
  • 5.3 Outsourcing
    • 5.3.1 Outsourcing market, 2016 - 2027 (USD Million)

Chapter 6 Regulatory Affairs Market: Company Size Segment Analysis

  • 6.1 Regulatory Affairs: Company Size Market Share Analysis, 2019 & 2027
  • 6.2 Small Sized
    • 6.2.1 Small companies based regulatory affairs market, 2016 - 2027 (USD Million)
  • 6.3 Medium Sized
    • 6.3.1 Medium-sized companies based regulatory affairs market, 2016 - 2027 (USD Million)
  • 6.4 Large Companies
    • 6.4.1 Large companies based regulatory affairs market, 2016 - 2027 (USD Million)

Chapter 7 Regulatory Affairs Market: Categories Segment Analysis

  • 7.1 Regulatory Affairs: Categories Market Share Analysis, 2019 & 2027
  • 7.2 Drugs
    • 7.2.1 Drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.1 Innovator drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.1.2 Clinical drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.1.3 Post market drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.2 Generic drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.2.1 Preclinical drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.2.2 Clinical drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.2.1.2.3 Post market drugs based regulatory affairs market, 2016 - 2027 (USD Million)
  • 7.3 Biologics
    • 7.3.1 Biologics based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.1 Biotech based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.1.2 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.1.3 Post market based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.2 ATMP based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.2.1 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.2.2 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.2.3 Post market based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.3 Biosimilar based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.3.1 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.3.2 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.3.1.3.3 Post market based regulatory affairs market, 2016 - 2027 (USD Million)
  • 7.4 Medical Devices
    • 7.4.1 Medical devices based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.1 Diagnostic based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.1.1 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.1.2 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.1.3 Post market based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.2 Therapeutic based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.2.1 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.2.2 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
      • 7.4.1.2.3 Post market based regulatory affairs market, 2016 - 2027 (USD Million)

Chapter 8 Regulatory Affairs Market: Product Stage Segment Analysis

  • 8.1 Regulatory Affairs: Product Stage Market Share Analysis, 2019 & 2027
  • 8.2 Preclinical
    • 8.2.1 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
  • 8.3 Clinical
    • 8.3.1 clinical based regulatory affairs market, 2016 - 2027 (USD Million)
  • 8.4 PMA
    • 8.4.1 PMA based regulatory affairs market, 2016 - 2027 (USD Million)

Chapter 9 Regulatory Affairs Market: Indication Segment Analysis

  • 9.1 Regulatory affairs: Indication Market Share Analysis, 2019 & 2027
  • 9.2 Oncology
    • 9.2.1 Oncology based regulatory affairs market, 2016 - 2027 (USD Million)
  • 9.3 Neurology
    • 9.3.1 Neurology based regulatory affairs market, 2016 - 2027 (USD Million)
  • 9.4 Cardiology
    • 9.4.1 cardiology based regulatory affairs market, 2016 - 2027 (USD Million)
  • 9.5 Immunology
    • 9.5.1 Immunology indication based regulatory affairs market, 2016 - 2027 (USD Million)
  • 9.6 Other Indications
    • 9.6.1 Other indication based regulatory affairs market, 2016 - 2027 (USD Million)

Chapter 10 Regulatory Affairs Market: End-use Segment Analysis

  • 10.1 Regulatory affairs: End-use Market Share Analysis, 2019 & 2027
  • 10.2 Medical Device Companies
    • 10.2.1 Medical device companies market, 2016 - 2027 (USD Million)
  • 10.3 Pharmaceutical Companies
    • 10.3.1 Pharmaceutical companies market, 2016 - 2027 (USD Million)
  • 10.4 Biotechnology Companies
    • 10.4.1 Biotechnology companies market, 2016 - 2027 (USD Million)

Chapter 11 Regulatory Affairs Market: Regional Analysis

  • 11.1 Regulatory affairs: Regional Market Share Analysis, 2019 & 2027
  • 11.2 North America
    • 11.2.1 North America regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.2.2 U.S.
      • 11.2.2.1 U.S. Regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.2.3 Canada
      • 11.2.3.1 Canada regulatory affairs market, 2016 - 2027 (USD Million)
  • 11.3 Europe
    • 11.3.1 Europe regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.2 U.K.
      • 11.3.2.1 U.K. regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.3 Germany
      • 11.3.3.1 Germany regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.4 France
      • 11.3.4.1 France regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.5 Italy
      • 11.3.5.1 Italy regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.6 Spain
      • 11.3.6.1 Spain regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.7 Russia
      • 11.3.7.1 Russia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.8 Turkey
      • 11.3.8.1 Turkey regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.9 The Netherlands
      • 11.3.9.1 The Netherlands regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.10 Switzerland
      • 11.3.10.1 Switzerland regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.3.11 Sweden
      • 11.3.11.1 Sweden regulatory affairs market, 2016 - 2027 (USD Million)
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.2 Japan
      • 11.4.2.1 Japan regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.3 China
      • 11.4.3.1 China regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.4 India
      • 11.4.4.1 India regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.5 Australia
      • 11.4.5.1 Australia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.6 South Korea
      • 11.4.6.1 South Korea regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.7 Indonesia
      • 11.4.7.1 Indonesia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.8 Malaysia
      • 11.4.8.1 Malaysia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.9 Singapore
      • 11.4.9.1 Singapore regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.10 Thailand
      • 11.4.10.1 Thailand regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.4.11 Taiwan
      • 11.4.11.1 Taiwan regulatory affairs market, 2016 - 2027 (USD Million)
  • 11.5 Latin America
    • 11.5.1 Latin America regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.5.2 Brazil
      • 11.5.2.1 Brazil regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.5.3 Mexico
      • 11.5.3.1 Mexico regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.5.4 Argentina
      • 11.5.4.1 Argentina regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.5.5 Colombia
      • 11.5.5.1 Colombia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.5.6 Chile
      • 11.5.6.1 Chile regulatory affairs market, 2016 - 2027 (USD Million)
  • 11.6 MEA
    • 11.6.1 MEA regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.6.2 South Africa
      • 11.6.2.1 South Africa regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.6.3 Saudi Arabia
      • 11.6.3.1 Saudi Arabia regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.6.4 UAE
      • 11.6.4.1 UAE regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.6.5 Egypt
      • 11.6.5.1 Egypt regulatory affairs market, 2016 - 2027 (USD Million)
    • 11.6.6 Israel
      • 11.6.6.1 Israel regulatory affairs market, 2016 - 2027 (USD Million)

Chapter 12 Company Profiles

  • 12.1 Accell Clinical Research, LLC.
    • 12.1.1 Company Overview
    • 12.1.2 Financial Performance
    • 12.1.3 Organization structure & team composition
      • 12.1.3.1 Team Composition
    • 12.1.4 Service Benchmarking
    • 12.1.5 Geographic Presence
    • 12.1.6 Strategic Initiatives
    • 12.1.7 SWOT
  • 12.2 GenPact Ltd.
    • 12.2.1 Company Overview
    • 12.2.2 Financial Performance
    • 12.2.3 Organization structure & team composition
      • 12.2.3.1 Team Composition
    • 12.2.4 Service Benchmarking
    • 12.2.5 Geographic Presence
    • 12.2.6 Strategic Initiatives
    • 12.2.7 SWOT
  • 12.3 Criterium, Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Financial Performance
    • 12.3.3 Organization structure & team composition
      • 12.3.3.1 Team Composition
    • 12.3.4 Service Benchmarking
    • 12.3.5 Geographic Presence
    • 12.3.6 SWOT
  • 12.4 PRA Health Sciences
    • 12.4.1 Company Overview
    • 12.4.2 Financial Performance
    • 12.4.3 Organization structure & team composition
      • 12.4.3.1 Team Composition
    • 12.4.4 Service Benchmarking
    • 12.4.5 Geographic Presence
    • 12.4.6 Strategic Initiatives
    • 12.4.7 SWOT
  • 12.5 Promedica International
    • 12.5.1 Company Overview
    • 12.5.2 Financial Performance
    • 12.5.3 Organization structure & team composition
      • 12.5.3.1 Team Composition
    • 12.5.4 Service Benchmarking
    • 12.5.5 Geographic Presence
    • 12.5.6 SWOT
  • 12.6 WuXi AppTec, Inc.
    • 12.6.1 Company Overview
    • 12.6.2 Financial Performance
    • 12.6.3 Organization structure & team composition
      • 12.6.3.1 Team Composition
    • 12.6.4 Service Benchmarking
    • 12.6.5 Geographic Presence
    • 12.6.6 Strategic Initiatives
    • 12.6.7 SWOT
  • 12.7 Medpace
    • 12.7.1 Company Overview
    • 12.7.2 Financial Performance
    • 12.7.3 Organization structure & team composition
      • 12.7.3.1 Team Composition
    • 12.7.4 Service Benchmarking
    • 12.7.5 Geographic Presence
    • 12.7.6 SWOT
  • 12.8 Charles River Laboratories International, Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Financial Performance
    • 12.8.3 Organization structure & team composition
      • 12.8.3.1 Team Composition
    • 12.8.4 Service Benchmarking
    • 12.8.5 Geographic Presence
    • 12.8.6 Strategic Initiatives
    • 12.8.7 SWOT
  • 12.9 Icon plc
    • 12.9.1 Company Overview
    • 12.9.2 Financial Performance
    • 12.9.3 Organization structure & team composition
      • 12.9.3.1 Team Composition
    • 12.9.4 Service Benchmarking
    • 12.9.5 Geographic Presence
    • 12.9.6 Strategic Initiatives
    • 12.9.7 SWOT
  • 12.10 Covance
    • 12.10.1 Company Overview
    • 12.10.2 Financial Performance
    • 12.10.3 Organization structure & team composition
      • 12.10.3.1 Team Composition
    • 12.10.4 Service Benchmarking
    • 12.10.5 Geographic Presence
    • 12.10.6 Strategic Initiatives
    • 12.10.7 SWOT
  • 12.11 Parexel International Corporation
    • 12.11.1 Company Overview
    • 12.11.2 Financial Performance
    • 12.11.3 Organization structure & team composition
      • 12.11.3.1 Team Composition
    • 12.11.4 Service Benchmarking
    • 12.11.5 Geographic Presence
    • 12.11.6 Strategic Initiatives
    • 12.11.7 SWOT
  • 12.12 Freyr
    • 12.12.1 Company Overview
    • 12.12.2 Financial Performance
    • 12.12.3 Organization structure & team composition
      • 12.12.3.1 Team Composition
    • 12.12.4 Service Benchmarking
    • 12.12.5 Geographic Presence
    • 12.12.6 Strategic Initiatives
    • 12.12.7 SWOT

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Regulatory affairs market snapshot (2019)
  • Fig. 9 Regulatory affairs market segmentation
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Number of Trials, By WHO Regions
  • Fig. 12 Personalized Medicine as a percentage of CDER approved novel molecules.
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 SWOT
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 18 Regulatory affairs market service outlook: Segment dashboard
  • Fig. 19 Regulatory affairs market: service movement analysis
  • Fig. 20 Regulatory consulting market, 2016 - 2027 (USD Million)
  • Fig. 21 Legal representation market, 2016 - 2027 (USD Million)
  • Fig. 22 Regulatory writing and publishing market, 2016 - 2027 (USD Million)
  • Fig. 23 Product registration and clinical trial application market, 2016 - 2027 (USD Million)
  • Fig. 24 Other regulatory services market, 2016 - 2027 (USD Million)
  • Fig. 25 Regulatory affairs market service provider outlook: Segment dashboard
  • Fig. 26 Regulatory affairs market: service provider movement analysis
  • Fig. 27 In-house regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 28 Outsourcing regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 29 Regulatory affairs market company size outlook: Segment dashboard
  • Fig. 30 Regulatory affairs market: Company Size movement analysis
  • Fig. 31 Small companies based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 32 Medium-sized company based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 33 Large companies based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 34 Regulatory affairs market categories outlook: Segment dashboard
  • Fig. 35 Regulatory affairs market: Categories movement analysis
  • Fig. 36 Drugs based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 37 Biologics based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 38 Medical devices based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 39 Regulatory affairs product stage outlook: Segment dashboard
  • Fig. 40 Regulatory affairs market: Product Stage movement analysis
  • Fig. 41 Preclinical based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 42 Clinical based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 43 PMA based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 44 Regulatory affairs market indication outlook: Segment dashboard
  • Fig. 45 Regulatory affairs market: indication movement analysis
  • Fig. 46 Oncology based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 47 Neurology based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 48 Cardiology based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 49 Immunology indication based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 50 Other indication based regulatory affairs market, 2016 - 2027 (USD Million)
  • Fig. 51 Regulatory affairs market end-use outlook: Segment dashboard
  • Fig. 52 Regulatory affairs market: end-use movement analysis
  • Fig. 53 Medical device companies market, 2016 - 2027 (USD Million)
  • Fig. 54 Pharmaceutical companies market, 2016 - 2027 (USD Million)
  • Fig. 55 Biotechnology companies market, 2016 - 2027 (USD Million)
  • Fig. 56 Regional market: Key takeaways
  • Fig. 57 Regional outlook, 2019 & 2027
  • Fig. 58 North America market, 2016 - 2027 (USD Million)
  • Fig. 59 U.S. market, 2016 - 2027 (USD Million)
  • Fig. 60 Canada market, 2016 - 2027 (USD Million)
  • Fig. 61 Europe market, 2016 - 2027 (USD Million)
  • Fig. 62 U.K. market, 2016 - 2027 (USD Million)
  • Fig. 63 Germany market, 2016 - 2027 (USD Million)
  • Fig. 64 France market, 2016 - 2027 (USD Million)
  • Fig. 65 Italy market, 2016 - 2027 (USD Million)
  • Fig. 66 Spain market, 2016 - 2027 (USD Million)
  • Fig. 67 Russia market, 2016 - 2027 (USD Million)
  • Fig. 68 Turkey market, 2016 - 2027 (USD Million)
  • Fig. 69 The Netherlands market, 2016 - 2027 (USD Million)
  • Fig. 70 Switzerland market, 2016 - 2027 (USD Million)
  • Fig. 71 Sweden market, 2016 - 2027 (USD Million)
  • Fig. 72 Asia Pacific market, 2016 - 2027 (USD Million)
  • Fig. 73 Japan market, 2016 - 2027 (USD Million)
  • Fig. 74 China market, 2016 - 2027 (USD Million)
  • Fig. 75 India market, 2016 - 2027 (USD Million)
  • Fig. 76 Australia market, 2016 - 2027 (USD Million)
  • Fig. 77 South Korea market, 2016 - 2027 (USD Million)
  • Fig. 78 Indonesia market, 2016 - 2027 (USD Million)
  • Fig. 79 Malaysia market, 2016 - 2027 (USD Million)
  • Fig. 80 Singapore market, 2016 - 2027 (USD Million)
  • Fig. 81 Thailand market, 2016 - 2027 (USD Million)
  • Fig. 82 Taiwan market, 2016 - 2027 (USD Million)
  • Fig. 83 Latin America market, 2016 - 2027 (USD Million)
  • Fig. 84 Brazil market, 2016 - 2027 (USD Million)
  • Fig. 85 Mexico market, 2016 - 2027 (USD Million)
  • Fig. 86 Argentina market, 2016 - 2027 (USD Million)
  • Fig. 87 Colombia market, 2016 - 2027 (USD Million)
  • Fig. 88 Chile market, 2016 - 2027 (USD Million)
  • Fig. 89 MEA market, 2016 - 2027 (USD Million)
  • Fig. 90 South Africa market, 2016 - 2027 (USD Million)
  • Fig. 91 Saudi Arabia market, 2016 - 2027 (USD Million)
  • Fig. 92 UAE market, 2016 - 2027 (USD Million)
  • Fig. 93 Egypt market, 2016 - 2027 (USD Million)
  • Fig. 94 Israel market, 2016 - 2027 (USD Million)
  • Fig. 95 Organization Structure - Accell Clinical Research, LLC
  • Fig. 96 SWOT - Accell Clinical Research, LLC
  • Fig. 97 Organization Structure - Genpact Ltd
  • Fig. 98 SWOT - Genpact
  • Fig. 99 Organization Structure - Criterium, Inc.
  • Fig. 100 SWOT - Criterium, Inc
  • Fig. 101 Organization Structure - PRA Health Sciences
  • Fig. 102 SWOT - PRA Health Sciences
  • Fig. 103 Organization Structure - Promedica International
  • Fig. 104 SWOT - Promedica International
  • Fig. 105 Organization Structure - WuXi AppTec
  • Fig. 106 SWOT - Wuxi AppTec
  • Fig. 107 Organization Structure - Medpace
  • Fig. 108 SWOT - Medpace
  • Fig. 109 Organization Structure - Charles River Laboratories International, Inc.
  • Fig. 110 SWOT - Charles River Laboratories International, Inc
  • Fig. 111 Organization Structure - ICON plc
  • Fig. 112 SWOT - ICON plc
  • Fig. 113 Organization Structure - Covance, Inc
  • Fig. 114 SWOT - Covance, Inc
  • Fig. 115 Organization Structure - PAREXEL International Corporation
  • Fig. 116 SWOT - PAREXEL International Corporation
  • Fig. 117 Organization Structure - Freyr
  • Fig. 118 SWOT - Freyr